Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response.MethodsWe included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2004
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/27041
- Acceso en línea:
- https://doi.org/10.1016/j.semarthrit.2003.11.002
https://repository.urosario.edu.co/handle/10336/27041
- Palabra clave:
- Systemic lupus erythematosus
Cytokines
TNF-?
IL-10IL12
Autoantibodies
SLEDAI
- Rights
- License
- Restringido (Acceso a grupos específicos)
id |
EDOCUR2_214a4493d3c38b04ddf3e9bb92289fd3 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/27041 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
580969d2-cc6b-4ffe-a1d8-9a3beec278cfdb6634cb-78db-456d-82d5-fa7140510037c5e15d68-2e79-46cc-994c-608ea4c1dc2311dd66da-4e02-4f6f-9171-5c31eb777d1b47d226c1-f36d-43c4-a449-590b2286830c194747786002020-08-19T14:40:50Z2020-08-19T14:40:50Z2004-06Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response.MethodsWe included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor (TNF) ?, interferon (IFN) ?, interleukin (IL)-12p70, IL-10, and IL-4, as well as anti-DNA, -Ro, -La, -RNP, and -Sm antibodies were determined by enzyme-linked immunosorbent assay. Disease activity was recorded according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and classified as very active (SLEDAI ? 13), moderately active (SLEDAI: 3–12), or inactive (SLEDAI ? 2).ResultsThe mean age of the patients was 34.2 ± 12.6 years, and the mean duration of disease was 4.9 ± 7.6 years. Twelve patients (23%), 20 patients (34.5%), and 20 patients (34.5%) had highly, moderately, and inactive SLE, respectively. Levels of IFN-?, TNF-?, and IL-12 were significantly higher in patients than in healthy controls (P < .03), as well as the IL-12/IL-10, IL-12/IL-4, IFN/IL-10, IFN/IL-4, TNF/IL-10, and TNF/IL-4 ratios (P < .01), suggesting a major participation of Th1 over Th2 cytokines. Nevertheless, a direct correlation between Th1 (IFN-? and TNF-?) and Th2 (IL-4 and IL-10) cytokines was observed in patients (r > .5, P < .01), indicating a mutual Th1-Th2 participation. TNF-? levels and the TNF/IL-10 ratio were higher in patients with inactive disease compared with patients with very active disease and controls (P < .04). IL-12 levels and IL-12/IL-4, as well as IL-12/IL-10, ratios were higher in patients with very active disease than in those with inactive SLE and controls (P < .01). IL-10 levels were associated with anti-DNA, anti-Ro, and anti-La response (P < .01).ConclusionOur results suggest that TNF-? could be a protective factor in SLE patients, whereas IL-12p70 participates in disease activity and IL-10 influences the autoimmune response (autoantibody production).application/pdfhttps://doi.org/10.1016/j.semarthrit.2003.11.002ISSN: 0049-0172EISSN: 1532-866Xhttps://repository.urosario.edu.co/handle/10336/27041engElsevier413No. 6404Seminars in Arthritis and RheumatismVol. 33Seminars in Arthritis and Rheumatism, ISSN: 0049-0172;EISSN: 1532-866X, Vol., 33 No.6 (2004); pp. 404-413https://www.sciencedirect.com/science/article/abs/pii/S0049017203002142Restringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecSeminars in Arthritis and Rheumatisminstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURSystemic lupus erythematosusCytokinesTNF-?IL-10IL12AutoantibodiesSLEDAITh1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?Citocinas Th1 / Th2 en pacientes con lupus eritematoso sistémico: ¿es protector el factor de necrosis tumoral ??articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Gómez, DianaCorrea, Paula A.Gómez, Luis MiguelCadena, JoséMolina, José F.Anaya, Juan-Manuel10336/27041oai:repository.urosario.edu.co:10336/270412021-08-13 23:21:38.785https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
dc.title.TranslatedTitle.spa.fl_str_mv |
Citocinas Th1 / Th2 en pacientes con lupus eritematoso sistémico: ¿es protector el factor de necrosis tumoral ?? |
title |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
spellingShingle |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? Systemic lupus erythematosus Cytokines TNF-? IL-10IL12 Autoantibodies SLEDAI |
title_short |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
title_full |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
title_fullStr |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
title_full_unstemmed |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
title_sort |
Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective? |
dc.subject.keyword.spa.fl_str_mv |
Systemic lupus erythematosus Cytokines TNF-? IL-10IL12 Autoantibodies SLEDAI |
topic |
Systemic lupus erythematosus Cytokines TNF-? IL-10IL12 Autoantibodies SLEDAI |
description |
Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response.MethodsWe included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor (TNF) ?, interferon (IFN) ?, interleukin (IL)-12p70, IL-10, and IL-4, as well as anti-DNA, -Ro, -La, -RNP, and -Sm antibodies were determined by enzyme-linked immunosorbent assay. Disease activity was recorded according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and classified as very active (SLEDAI ? 13), moderately active (SLEDAI: 3–12), or inactive (SLEDAI ? 2).ResultsThe mean age of the patients was 34.2 ± 12.6 years, and the mean duration of disease was 4.9 ± 7.6 years. Twelve patients (23%), 20 patients (34.5%), and 20 patients (34.5%) had highly, moderately, and inactive SLE, respectively. Levels of IFN-?, TNF-?, and IL-12 were significantly higher in patients than in healthy controls (P < .03), as well as the IL-12/IL-10, IL-12/IL-4, IFN/IL-10, IFN/IL-4, TNF/IL-10, and TNF/IL-4 ratios (P < .01), suggesting a major participation of Th1 over Th2 cytokines. Nevertheless, a direct correlation between Th1 (IFN-? and TNF-?) and Th2 (IL-4 and IL-10) cytokines was observed in patients (r > .5, P < .01), indicating a mutual Th1-Th2 participation. TNF-? levels and the TNF/IL-10 ratio were higher in patients with inactive disease compared with patients with very active disease and controls (P < .04). IL-12 levels and IL-12/IL-4, as well as IL-12/IL-10, ratios were higher in patients with very active disease than in those with inactive SLE and controls (P < .01). IL-10 levels were associated with anti-DNA, anti-Ro, and anti-La response (P < .01).ConclusionOur results suggest that TNF-? could be a protective factor in SLE patients, whereas IL-12p70 participates in disease activity and IL-10 influences the autoimmune response (autoantibody production). |
publishDate |
2004 |
dc.date.created.spa.fl_str_mv |
2004-06 |
dc.date.accessioned.none.fl_str_mv |
2020-08-19T14:40:50Z |
dc.date.available.none.fl_str_mv |
2020-08-19T14:40:50Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.semarthrit.2003.11.002 |
dc.identifier.issn.none.fl_str_mv |
ISSN: 0049-0172 EISSN: 1532-866X |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/27041 |
url |
https://doi.org/10.1016/j.semarthrit.2003.11.002 https://repository.urosario.edu.co/handle/10336/27041 |
identifier_str_mv |
ISSN: 0049-0172 EISSN: 1532-866X |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
413 |
dc.relation.citationIssue.none.fl_str_mv |
No. 6 |
dc.relation.citationStartPage.none.fl_str_mv |
404 |
dc.relation.citationTitle.none.fl_str_mv |
Seminars in Arthritis and Rheumatism |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 33 |
dc.relation.ispartof.spa.fl_str_mv |
Seminars in Arthritis and Rheumatism, ISSN: 0049-0172;EISSN: 1532-866X, Vol., 33 No.6 (2004); pp. 404-413 |
dc.relation.uri.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/abs/pii/S0049017203002142 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_16ec |
dc.rights.acceso.spa.fl_str_mv |
Restringido (Acceso a grupos específicos) |
rights_invalid_str_mv |
Restringido (Acceso a grupos específicos) http://purl.org/coar/access_right/c_16ec |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier |
dc.source.spa.fl_str_mv |
Seminars in Arthritis and Rheumatism |
institution |
Universidad del Rosario |
dc.source.instname.none.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.none.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167431386497024 |